Live Micron Technology Inc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Panbela Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Panbela Therapeutics, Inc.

PBLA

Panbela Therapeutics, Inc.

About Panbela Therapeutics, Inc.

Panbela Therapeutics develops innovative therapeutics targeting dysregulated polyamine metabolism for cancer and autoimmune diseases. Its core assets include ivospemin and eflornithine-based formulations, aimed at treating pancreatic, colon, ovarian, and other cancers, as well as autoimmune conditions like Type 1 diabetes. The company focuses on clinical-stage drug development, leveraging orphan drug designations and strategic collaborations to address unmet medical needs with potential preventive and treatment options.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Panbela Therapeutics, Inc.

1
1
Panbela Therapeutics, Inc. Panbela Therapeutics Reports Mixed Financial Results, Seeks Additional Capital

Via official filing (AI summary) | over 1 year ago | 0 comments